Interface Biologics Inc. (IBI) is a commercial stage privately held company that develops transformative biomedical polymer technologies
to improve the safety and effectiveness of medical devices.
IBI’s primary technology focus areas are anti-thrombogenic additives that reduce thrombosis in blood
contacting medical devices and polymer enabled drug delivery platforms.
IBI’s technology has been licensed to a number of OEM medical device manufacturers including AngioDynamics for vascular access catheters and Fresenius Medical Care for dialysis systems. Additionally, IBI is partnering with Qualimed on the development of a drug coated balloon and Southern Implants on the development of an anti-microbial dental implant.
We are located in the MaRS Discovery District
Interface Biologics, Inc.
MaRS Centre, South Tower
101 College Street, Suite 300
Toronto, ON, M5G 1L7
Main Line (416) 673-8170
Fax (416) 977-1329